Wednesday, March 01, 2017 3:58:24 PM
John F. Milligan
We're particularly excited about the role that TAF will play. With a small daily dose and improved side effect profile, it is ideal for resource-constrained areas of the world and requires only one-tenth of the manufacturing capacity to supply the same number of patients.
TAF's manufacturing efficiency bodes well for the future profit margins in the HIV business. Now how about safety? TAF is both safer for renal health and bone density. This abstract from CROI illustrates the point clearly. 0 out of 866 patients developed clinically significant renal issues on TAF, whereas 12 out of 867 patients developed renal issues on TDF. This is statistically significant, and the efficacy results are similar. All you need to know is TAF is a safer version of TDF, and that safety is paramount in HIV treatment.
In the HCV market, side effects are important. However, they are even more crucial in HIV because the disease is chronic. In other words, treatment durations are decades rather than a few weeks. Drug-drug interactions, side effects, PK and PD data, and various other factors play a huge role in these lifetime treatment fields. TAF solved long-term concerns related to renal and bone damage seen with TDF treatments, leading to fast uptake.
When Gilead released TAF, it was quickly adopted as a preferred treatment in the US Department of Health & Human Services (DHHS) and International Antiviral Society (IAS) guidelines. It has also been adopted in the guidelines of a variety of other countries such as Germany, the UK, Spain, and Italy. In addition, guidelines are starting to label TDF-backed regimens as alternative treatments. A quote from the Wells Fargo broker conference back in September 2016 illustrates the importance of this:
Recent GSK News
- BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million • GlobeNewswire Inc. • 05/07/2024 05:00:00 AM
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer • Business Wire • 03/16/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 05:48:43 PM
- GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise • Business Wire • 03/07/2024 05:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 11:13:57 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 04:11:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 06:09:20 PM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 03/05/2024 05:30:25 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 05:10:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 11:10:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/01/2024 03:29:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/01/2024 02:55:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 11:27:26 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 11:27:24 AM
- Shares of WW International Plummet after Oprah Exits, EA Announces Workforce Reduction and Restructuring Plan, and Latest News • IH Market News • 02/29/2024 11:11:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 03:38:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 11:39:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/22/2024 03:45:43 PM
- Cisco Systems Stock Drops 5% Following Restructuring Plan, Berkshire Trims Apple Stake, and Latest News • IH Market News • 02/15/2024 11:34:25 AM
- Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 02/07/2024 09:01:00 PM
- FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) • GlobeNewswire Inc. • 02/07/2024 12:00:00 PM
- GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk • Business Wire • 02/06/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 11:51:33 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM